impact factor
logo
 

LER & CER: letter to Editor Rheumatology

 

Comment on: Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis by Humby et al.


1, 2, 3

 

  1. Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey. docemineduran@gmail.com
  2. Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Ankara, Turkey.
  3. Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey.

CER14777
LER & CER: letter to Editor Rheumatology

Free to view
(click on article PDF icon to read the article)

PMID: 34494954 [PubMed]

Received: 04/05/2021
Accepted : 09/07/2021
In Press: 07/09/2021

Rheumatology Article